IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 149 filers reported holding IMMUNOVANT INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,151,068 | +81.2% | 56,032 | -10.5% | 0.00% | +100.0% |
| Q2 2023 | $1,187,408 | +51.9% | 62,594 | +24.2% | 0.00% | 0.0% |
| Q1 2023 | $781,734 | -10.0% | 50,402 | +3.0% | 0.00% | 0.0% |
| Q4 2022 | $868,171 | +285.9% | 48,911 | +21.4% | 0.00% | – |
| Q3 2022 | $225,000 | +55.2% | 40,279 | +8.8% | 0.00% | – |
| Q2 2022 | $145,000 | -24.5% | 37,013 | +6.1% | 0.00% | – |
| Q1 2022 | $192,000 | -4.0% | 34,873 | +48.6% | 0.00% | – |
| Q4 2021 | $200,000 | +7.5% | 23,460 | +9.4% | 0.00% | – |
| Q3 2021 | $186,000 | -74.3% | 21,440 | -68.7% | 0.00% | – |
| Q2 2021 | $724,000 | -6.6% | 68,579 | +42.0% | 0.00% | – |
| Q1 2021 | $775,000 | -74.4% | 48,312 | -26.4% | 0.00% | -100.0% |
| Q4 2020 | $3,029,000 | +120.1% | 65,604 | +67.8% | 0.00% | 0.0% |
| Q3 2020 | $1,376,000 | +323.4% | 39,086 | +192.2% | 0.00% | – |
| Q2 2020 | $325,000 | – | 13,378 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |